6.
Djinovic-Carugo K, Young P, Gautel M, Saraste M
. Structure of the alpha-actinin rod: molecular basis for cross-linking of actin filaments. Cell. 1999; 98(4):537-46.
DOI: 10.1016/s0092-8674(00)81981-9.
View
7.
Verhaart I, Aartsma-Rus A
. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019; 15(7):373-386.
DOI: 10.1038/s41582-019-0203-3.
View
8.
Koczok K, Mero G, Szabo G, Madar L, Gombos E, Ajzner E
. A novel point mutation affecting Asn76 of dystrophin protein leads to dystrophinopathy. Neuromuscul Disord. 2018; 28(2):129-136.
DOI: 10.1016/j.nmd.2017.12.003.
View
9.
Adzhubei I, Schmidt S, Peshkin L, Ramensky V, Gerasimova A, Bork P
. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4):248-9.
PMC: 2855889.
DOI: 10.1038/nmeth0410-248.
View
10.
Guevara-Fujita M, Huaman-Dianderas F, Obispo D, Sanchez R, Barrenechea V, Rojas-Malaga D
. MLPA followed by target-NGS to detect mutations in the dystrophin gene of Peruvian patients suspected of DMD/DMB. Mol Genet Genomic Med. 2021; 9(9):e1759.
PMC: 8457708.
DOI: 10.1002/mgg3.1759.
View
11.
Fagerberg L, Hallstrom B, Oksvold P, Kampf C, Djureinovic D, Odeberg J
. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2013; 13(2):397-406.
PMC: 3916642.
DOI: 10.1074/mcp.M113.035600.
View
12.
Legardinier S, Raguenes-Nicol C, Tascon C, Rocher C, Hardy S, Hubert J
. Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin. J Mol Biol. 2009; 389(3):546-58.
DOI: 10.1016/j.jmb.2009.04.025.
View
13.
Bucher F, Friedlander M, Aguilar E, Kurihara T, Krohne T, Usui Y
. The long dystrophin gene product Dp427 modulates retinal function and vascular morphology in response to age and retinal ischemia. Neurochem Int. 2019; 129:104489.
DOI: 10.1016/j.neuint.2019.104489.
View
14.
Zhao J, Kodippili K, Yue Y, Hakim C, Wasala L, Pan X
. Dystrophin contains multiple independent membrane-binding domains. Hum Mol Genet. 2016; 25(17):3647-3653.
PMC: 5216612.
DOI: 10.1093/hmg/ddw210.
View
15.
Wagner K, Kuntz N, Koenig E, East L, Upadhyay S, Han B
. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021; 64(3):285-292.
PMC: 9290993.
DOI: 10.1002/mus.27347.
View
16.
Corvelo A, Hallegger M, Smith C, Eyras E
. Genome-wide association between branch point properties and alternative splicing. PLoS Comput Biol. 2010; 6(11):e1001016.
PMC: 2991248.
DOI: 10.1371/journal.pcbi.1001016.
View
17.
Chang W, Iannaccone S, Lau K, Masters B, McCabe T, McMillan K
. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A. 1996; 93(17):9142-7.
PMC: 38609.
DOI: 10.1073/pnas.93.17.9142.
View
18.
Gao Q, McNally E
. The Dystrophin Complex: Structure, Function, and Implications for Therapy. Compr Physiol. 2015; 5(3):1223-39.
PMC: 4767260.
DOI: 10.1002/cphy.c140048.
View
19.
Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A
. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021; 7(1):13.
PMC: 10557455.
DOI: 10.1038/s41572-021-00248-3.
View
20.
Okubo M, Minami N, Goto K, Goto Y, Noguchi S, Mitsuhashi S
. Corrigendum: Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: validation analysis of DMD mutations. J Hum Genet. 2017; 62(10):931-933.
PMC: 7609325.
DOI: 10.1038/jhg.2017.54.
View